Baidu
map

急重症科指南

订阅

MedSci主页 / 所有栏目 / 急重症科指南

2020 SRLF专家共识指南：重症监护室内血管内导管的管理

2020-09-07 Ann Intensive Care . 2020 Sep 7;10(1):118.

重症监护室血管内导管

2020年9月，法国重症医学学会(SRLF)发布了重症监护室内血管内导管的管理共识指南，文章主要目的是解决ICU内应用血管内装置的管理问题。

中文标题：

2020 SRLF专家共识指南：重症监护室内血管内导管的管理

英文标题：

Expert consensus-based clinical practice guidelines management of intravascular catheters in the intensive care unit

发布机构：

发布日期：

2020-09-07

简要介绍：

2020年9月，法国重症医学学会(SRLF)发布了重症监护室内血管内导管的管理共识指南，文章主要目的是解决ICU内应用血管内装置的管理问题。

相关资料下载：
[AttachmentFileName(sort=1, fileName=2020 SRLF专家共识指南：重症监护室内血管内导管的管理.pdf)] GetToolGuiderByIdResponse(projectId=1, id=0969a1c0019e312b, title=2020 SRLF专家共识指南：重症监护室内血管内导管的管理, enTitle=Expert consensus-based clinical practice guidelines management of intravascular catheters in the intensive care unit, guiderFrom=Ann Intensive Care . 2020 Sep 7;10(1):118., authorId=0, author=, summary=2020年9月，法国重症医学学会(SRLF)发布了重症监护室内血管内导管的管理共识指南，文章主要目的是解决ICU内应用血管内装置的管理问题。, cover=https://img.medsci.cn/2020920/1600613483812_2020535.jpg, journalId=0, articlesId=null, associationId=0, associationName=, associationIntro=, copyright=0, guiderPublishedTime=Mon Sep 07 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>2020年9月，法国重症医学学会(SRLF)发布了重症监护室内血管内导管的管理共识指南，文章主要目的是解决ICU内应用血管内装置的管理问题。</p> </div> </div> </div>, tagList=[TagDto(tagId=35207, tagName=重症监护室), TagDto(tagId=100687, tagName=血管内导管)], categoryList=[CategoryDto(categoryId=38, categoryName=急重症科, tenant=100), CategoryDto(categoryId=79, categoryName=护理, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=100687, guiderKeyword=血管内导管, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=4, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=8282, appHits=428, showAppHits=0, pcHits=1171, showPcHits=7854, likes=4, shares=27, comments=30, approvalStatus=1, publishedTime=Sun Sep 20 23:45:29 CST 2020, publishedTimeString=2020-09-07, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Sun Sep 20 22:51:30 CST 2020, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 21:22:01 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2020 SRLF专家共识指南：重症监护室内血管内导管的管理.pdf)])
2020 SRLF专家共识指南：重症监护室内血管内导管的管理.pdf
下载请点击：
评论区 (22)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1207128, encodeId=9925120e128f6, content=学习了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211220/34dc3395cbdc499d89c489c063269dd6/050ea6ea2df143eaa7f141a7ebb4d0bc.jpg, createdBy=94156413226, createdName=洁巴子, createdTime=Wed Mar 30 09:45:03 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188727, encodeId=4c591188e27c9, content=👄, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9c36452287, createdName=ms5000001611813221, createdTime=Fri Jan 28 02:25:34 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061707, encodeId=9e761061e0740, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=40a45631090, createdName=ms5000002099118544, createdTime=Tue Oct 19 08:23:15 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056667, encodeId=308d105666e9e, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Thu Sep 30 23:52:22 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1016413, encodeId=0d87101641381, content=想看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210910/78cc3351c3444ee0a43ff7771861f456/251d3cf274c5473a9e1c6a4e77798b66.jpg, createdBy=fdd25601853, createdName=空空男人, createdTime=Fri Sep 10 21:53:25 CST 2021, time=2021-09-10, status=1, ipAttribution=)]
    2022-03-30 洁巴子

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1207128, encodeId=9925120e128f6, content=学习了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211220/34dc3395cbdc499d89c489c063269dd6/050ea6ea2df143eaa7f141a7ebb4d0bc.jpg, createdBy=94156413226, createdName=洁巴子, createdTime=Wed Mar 30 09:45:03 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188727, encodeId=4c591188e27c9, content=👄, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9c36452287, createdName=ms5000001611813221, createdTime=Fri Jan 28 02:25:34 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061707, encodeId=9e761061e0740, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=40a45631090, createdName=ms5000002099118544, createdTime=Tue Oct 19 08:23:15 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056667, encodeId=308d105666e9e, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Thu Sep 30 23:52:22 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1016413, encodeId=0d87101641381, content=想看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210910/78cc3351c3444ee0a43ff7771861f456/251d3cf274c5473a9e1c6a4e77798b66.jpg, createdBy=fdd25601853, createdName=空空男人, createdTime=Fri Sep 10 21:53:25 CST 2021, time=2021-09-10, status=1, ipAttribution=)]
    2022-01-28 ms5000001611813221

    👄

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1207128, encodeId=9925120e128f6, content=学习了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211220/34dc3395cbdc499d89c489c063269dd6/050ea6ea2df143eaa7f141a7ebb4d0bc.jpg, createdBy=94156413226, createdName=洁巴子, createdTime=Wed Mar 30 09:45:03 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188727, encodeId=4c591188e27c9, content=👄, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9c36452287, createdName=ms5000001611813221, createdTime=Fri Jan 28 02:25:34 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061707, encodeId=9e761061e0740, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=40a45631090, createdName=ms5000002099118544, createdTime=Tue Oct 19 08:23:15 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056667, encodeId=308d105666e9e, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Thu Sep 30 23:52:22 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1016413, encodeId=0d87101641381, content=想看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210910/78cc3351c3444ee0a43ff7771861f456/251d3cf274c5473a9e1c6a4e77798b66.jpg, createdBy=fdd25601853, createdName=空空男人, createdTime=Fri Sep 10 21:53:25 CST 2021, time=2021-09-10, status=1, ipAttribution=)]
    2021-10-19 ms5000002099118544

    好

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1207128, encodeId=9925120e128f6, content=学习了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211220/34dc3395cbdc499d89c489c063269dd6/050ea6ea2df143eaa7f141a7ebb4d0bc.jpg, createdBy=94156413226, createdName=洁巴子, createdTime=Wed Mar 30 09:45:03 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188727, encodeId=4c591188e27c9, content=👄, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9c36452287, createdName=ms5000001611813221, createdTime=Fri Jan 28 02:25:34 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061707, encodeId=9e761061e0740, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=40a45631090, createdName=ms5000002099118544, createdTime=Tue Oct 19 08:23:15 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056667, encodeId=308d105666e9e, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Thu Sep 30 23:52:22 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1016413, encodeId=0d87101641381, content=想看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210910/78cc3351c3444ee0a43ff7771861f456/251d3cf274c5473a9e1c6a4e77798b66.jpg, createdBy=fdd25601853, createdName=空空男人, createdTime=Fri Sep 10 21:53:25 CST 2021, time=2021-09-10, status=1, ipAttribution=)]
    2021-09-30 一己怀

    谢谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1207128, encodeId=9925120e128f6, content=学习了 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211220/34dc3395cbdc499d89c489c063269dd6/050ea6ea2df143eaa7f141a7ebb4d0bc.jpg, createdBy=94156413226, createdName=洁巴子, createdTime=Wed Mar 30 09:45:03 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188727, encodeId=4c591188e27c9, content=👄, beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b9c36452287, createdName=ms5000001611813221, createdTime=Fri Jan 28 02:25:34 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061707, encodeId=9e761061e0740, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=40a45631090, createdName=ms5000002099118544, createdTime=Tue Oct 19 08:23:15 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056667, encodeId=308d105666e9e, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Thu Sep 30 23:52:22 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1016413, encodeId=0d87101641381, content=想看, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210910/78cc3351c3444ee0a43ff7771861f456/251d3cf274c5473a9e1c6a4e77798b66.jpg, createdBy=fdd25601853, createdName=空空男人, createdTime=Fri Sep 10 21:53:25 CST 2021, time=2021-09-10, status=1, ipAttribution=)]
    2021-09-10 空空男人

    想看

    0

以上为热门评论，梅斯医学App还有更多内容

相关指南

2019 AHA科学声明：重症监护室中老年患者的管理—老年综合征

美国心脏协会(AHA,American Heart Association) · 2019-12-09

SCCN：2012重症监护室设计指南

美国重症医学会(SCCM,Society of Critical Care Medicine) · 2012-05-11

拓展阅读

SCCN：2011血管内导管相关感染的预防指南

美国重症医学会(SCCM,Society of Critical Care Medicine) · 2011-10-01

血管内导管同品种对比临床评价技术审查指导原则

国家药品监督管理局医疗器械技术审评中心 · 2021-09-07

Baidu
map
Baidu
map
Baidu
map